Replies to post #2398 on Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

IMO, it’s reasonable to surmise that ENTA is unwilling to dedicate much effort to finding a second HBV agent, and is prepared out-license EDP-514 on suitable terms.

It might have been different if EDP-235 had already been approved or already showed stellar phase 3 data but sometimes you have to deal with fiscal reality and corporate capabilities. A bit disappointing but not unexpected.

• Presents New Preclinical In Vivo Data Demonstrating EDP-235’s Efficacy and Prevention of COVID-19 Transmission

It would be a big deal if EDP-235 was shown to limit transmission of Covid.